Company News Summary
Imugene Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results
27 Jun 2022 | 08:34:00 | Associate analysts | Increase | Decrease | 
Original announcement: Final HER-Vaxx Phase 2 Trial Overall Survival Results
Imugene presented positive final overall survival data from its Phase 2 study of HER-Vaxx in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer following analysis of safety and efficacy data. The final analysis results from the randomised clinical HERIZON study, which was designed with a specified 1-sided false positive probability of 0.10, showed a 41.5% survival benefit for patients treated with HERVaxx plus SOC chemotherapy compared to SOC chemotherapy alone. This translated into an overall survival HR of 0.585 (80% 2-sided CI: 0.368, 0.930) with a statistically significant p-value of 0.066. There was no difference in safety events between the two treatment arms, suggesting that HER-Vaxx does not add toxicity to SOC chemotherapy.
See more ASX300 News Announcements